메뉴 건너뛰기




Volumn 34, Issue 1, 2010, Pages 24-34

Referral criteria for benign prostatic hyperplasia in primary care;Criterios de derivación en hiperplasia benigna de próstata para atención primaria

(8)  Castineiras Fernandez J a,b   Cozar Olmo, J M b,c   Fernandez Pro A d,e   Martin J A e,f   Brenes Bermudez F J g,h   Naval Pulido, E h,i   Molero, J M j,k   Perez Morales D g,k  


Author keywords

Benign prostatic hyperplasia; Consensus; Primary care; Urology

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

EID: 77952309911     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(10)70007-3     Document Type: Article
Times cited : (23)

References (51)
  • 2
    • 37649023663 scopus 로고    scopus 로고
    • Hiperplasia benigna de próstata. Abordaje por el médico de Atención Primaria
    • Brenes F.J., Pérez N., Pimienta M., and Dios J.M. Hiperplasia benigna de próstata. Abordaje por el médico de Atención Primaria. SEMERGEN 33 (2007) 529-539
    • (2007) SEMERGEN , vol.33 , pp. 529-539
    • Brenes, F.J.1    Pérez, N.2    Pimienta, M.3    Dios, J.M.4
  • 3
    • 0030064611 scopus 로고    scopus 로고
    • Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men
    • Jacobsen S.J., Girman C.J., Guess H.A., Rhodes T., Oesterling J.E., and Lieber M.M. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 155 (1996) 595-600
    • (1996) J Urol , vol.155 , pp. 595-600
    • Jacobsen, S.J.1    Girman, C.J.2    Guess, H.A.3    Rhodes, T.4    Oesterling, J.E.5    Lieber, M.M.6
  • 4
    • 0031400391 scopus 로고    scopus 로고
    • Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: Evidence from the ICS-'BPH' Study. International Continence Society-- Benign Prostatic Hyperplasia
    • Donovan J.L., Kay H.E., Peters T.J., Abrams P., Coast J., Matos-Ferreira A., et al. Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: Evidence from the ICS-'BPH' Study. International Continence Society-- Benign Prostatic Hyperplasia. Br J Urol 80 (1997) 712-721
    • (1997) Br J Urol , vol.80 , pp. 712-721
    • Donovan, J.L.1    Kay, H.E.2    Peters, T.J.3    Abrams, P.4    Coast, J.5    Matos-Ferreira, A.6
  • 6
    • 24344471838 scopus 로고    scopus 로고
    • Epidemilogía de la hiperplasia benigna de próstata
    • Chicharro J.A., and Burgos R. Epidemilogía de la hiperplasia benigna de próstata. Medicine 7 (1997) 3-8
    • (1997) Medicine , vol.7 , pp. 3-8
    • Chicharro, J.A.1    Burgos, R.2
  • 7
    • 5144229259 scopus 로고    scopus 로고
    • EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)
    • Madersbacher S., Alivizatos G., Nordling J., Sanz C.R., Emberton M., and De la Rosette J.J. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
    • (2004) Eur Urol , vol.46 , pp. 547-554
    • Madersbacher, S.1    Alivizatos, G.2    Nordling, J.3    Sanz, C.R.4    Emberton, M.5    De la Rosette, J.J.6
  • 8
    • 0021149603 scopus 로고
    • The development of human benign prostatic hyperplasia with age
    • Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
    • (1984) J Urol , vol.132 , pp. 474-479
    • Berry, S.J.1    Coffey, D.S.2    Walsh, P.C.3    Ewing, L.L.4
  • 9
    • 0024832529 scopus 로고
    • Etiology and disease process of benign prostatic hyperplasia
    • Isaacs J.T., and Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2 (1989) 33-50
    • (1989) Prostate , Issue.SUPPL. 2 , pp. 33-50
    • Isaacs, J.T.1    Coffey, D.S.2
  • 10
    • 33845334529 scopus 로고    scopus 로고
    • Validez de las pruebas utilizadas en el diagnóstico inicial y su concordancia con el diagnóstico final en pacientes con sospecha de hiperplasia benigna de próstata
    • Carballido J.A., Badia X., Gimeno A., Regadera L., Dal-Ré R., and Guilera M. Validez de las pruebas utilizadas en el diagnóstico inicial y su concordancia con el diagnóstico final en pacientes con sospecha de hiperplasia benigna de próstata. Actas Urol Esp 30 (2006) 667-674
    • (2006) Actas Urol Esp , vol.30 , pp. 667-674
    • Carballido, J.A.1    Badia, X.2    Gimeno, A.3    Regadera, L.4    Dal-Ré, R.5    Guilera, M.6
  • 11
    • 2542642296 scopus 로고    scopus 로고
    • British Association of Urological Surgeons. Guideline for the primary care management of male lower urinary tract symptoms
    • Speakman M.J., Kirby R.S., Joyce A., Abrams P., and Pocock R. British Association of Urological Surgeons. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 93 (2004) 985-990
    • (2004) BJU Int , vol.93 , pp. 985-990
    • Speakman, M.J.1    Kirby, R.S.2    Joyce, A.3    Abrams, P.4    Pocock, R.5
  • 13
    • 0004784411 scopus 로고    scopus 로고
    • Clinical manifestations and indications for treatment
    • Lepor H. (Ed), WB Saunders, Philadelphia
    • Jepsen J.V., and Bruskewitz R.C. Clinical manifestations and indications for treatment. In: Lepor H. (Ed). Prostatic Diseases (2000), WB Saunders, Philadelphia 127-142
    • (2000) Prostatic Diseases , pp. 127-142
    • Jepsen, J.V.1    Bruskewitz, R.C.2
  • 14
    • 0026591918 scopus 로고
    • The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association
    • Barry M.J., Fowler Jr. F.J., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L., Mebust W.K., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148 (1992) 1549-1557
    • (1992) J Urol , vol.148 , pp. 1549-1557
    • Barry, M.J.1    Fowler Jr., F.J.2    O'Leary, M.P.3    Bruskewitz, R.C.4    Holtgrewe, H.L.5    Mebust, W.K.6
  • 15
    • 0031054573 scopus 로고    scopus 로고
    • Ten-language translation and harmonization of the International Prostate Symptom Score: developing a methodology for multinational clinical trials
    • Badia X., García-Losa M., and Dal-Re R. Ten-language translation and harmonization of the International Prostate Symptom Score: developing a methodology for multinational clinical trials. Eur Urol 31 (1997) 129-140
    • (1997) Eur Urol , vol.31 , pp. 129-140
    • Badia, X.1    García-Losa, M.2    Dal-Re, R.3
  • 16
    • 0028865153 scopus 로고
    • Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?
    • Barry M.J., Williford W.O., Chang Y., Machi M., Jones K.M., Walker-Corkery E., et al. Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol 154 (1995) 1770-1774
    • (1995) J Urol , vol.154 , pp. 1770-1774
    • Barry, M.J.1    Williford, W.O.2    Chang, Y.3    Machi, M.4    Jones, K.M.5    Walker-Corkery, E.6
  • 18
    • 36148931542 scopus 로고    scopus 로고
    • Diagnóstico de la patología habitual de la glándula prostática
    • LXI
    • Vargas C., and Vilana R. Diagnóstico de la patología habitual de la glándula prostática. Jano (2001) 49-54 LXI
    • (2001) Jano , pp. 49-54
    • Vargas, C.1    Vilana, R.2
  • 19
    • 0028256194 scopus 로고
    • Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
    • Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283-1290
    • (1994) J Urol , vol.151 , pp. 1283-1290
    • Catalona, W.J.1    Richie, J.P.2    Ahmann, F.R.3    Hudson, M.A.4    Scardino, P.T.5    Flanigan, R.C.6
  • 20
    • 0347882750 scopus 로고    scopus 로고
    • The long-term effect of doxazosin, finasteride, and combination therapy on the clinicalprogression of benign prostatic hyperplasia
    • McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinicalprogression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2388
    • (2003) N Engl J Med , vol.349 , pp. 2387-2388
    • McConnell, J.D.1    Roehrborn, C.G.2    Bautista, O.M.3    Andriole Jr., G.L.4    Dixon, C.M.5    Kusek, J.W.6
  • 21
    • 0037259307 scopus 로고    scopus 로고
    • Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men
    • Ku J.H., Kim M.E., Lee N.K., Park Y.H., and Ahn J.O. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 61 (2003) 132-136
    • (2003) Urology , vol.61 , pp. 132-136
    • Ku, J.H.1    Kim, M.E.2    Lee, N.K.3    Park, Y.H.4    Ahn, J.O.5
  • 22
    • 31944437498 scopus 로고    scopus 로고
    • Chronic Prostatitis Collaborative Research Network Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome
    • Nadler R.B., Collins M.M., Propert K.J., Mikolajczyk S.D., Knauss J.S., Landis J.R., et al. Chronic Prostatitis Collaborative Research Network Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology 67 (2006) 337-342
    • (2006) Urology , vol.67 , pp. 337-342
    • Nadler, R.B.1    Collins, M.M.2    Propert, K.J.3    Mikolajczyk, S.D.4    Knauss, J.S.5    Landis, J.R.6
  • 23
    • 0027244140 scopus 로고
    • Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
    • Oesterling J.E., Jacobsen S.J., Chute C.G., Guess H.A., Girman C.J., Panser L.A., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
    • (1993) JAMA , vol.270 , pp. 860-864
    • Oesterling, J.E.1    Jacobsen, S.J.2    Chute, C.G.3    Guess, H.A.4    Girman, C.J.5    Panser, L.A.6
  • 24
    • 0027845508 scopus 로고
    • Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial
    • Guess H.A., Heyse J.F., Gormley G.J., Stoner E., and Oesterling J.E. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 20 (1993) 627-636
    • (1993) Urol Clin North Am , vol.20 , pp. 627-636
    • Guess, H.A.1    Heyse, J.F.2    Gormley, G.J.3    Stoner, E.4    Oesterling, J.E.5
  • 25
    • 33646006372 scopus 로고    scopus 로고
    • Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alphareductase inhibitor dutasteride
    • Andriole G.L., Marberger M., and Roehrborn C.G. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alphareductase inhibitor dutasteride. J Urol 175 (2006) 1657-1662
    • (2006) J Urol , vol.175 , pp. 1657-1662
    • Andriole, G.L.1    Marberger, M.2    Roehrborn, C.G.3
  • 26
    • 72149105120 scopus 로고    scopus 로고
    • ¿Hay que recomendar cribado de cáncer de próstata en individuos asintomáticos?
    • Brenes F.J. ¿Hay que recomendar cribado de cáncer de próstata en individuos asintomáticos?. Siete Días Médicos 701 (2007) 58-60
    • (2007) Siete Días Médicos , vol.701 , pp. 58-60
    • Brenes, F.J.1
  • 28
    • 84892251112 scopus 로고    scopus 로고
    • American Urological Association (AUA)
    • Prostate-specific antigen (PSA) best practice policy
    • Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park) 14 (2000) 267-272
    • (2000) Oncology (Williston Park) , vol.14 , pp. 267-272
  • 29
    • 32444434459 scopus 로고    scopus 로고
    • American Cancer Society guidelines for the early detection of cancer, 2006
    • Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 56 (2006) 11-25
    • (2006) CA Cancer J Clin , vol.56 , pp. 11-25
    • Smith, R.A.1    Cokkinides, V.2    Eyre, H.J.3
  • 30
    • 46649118317 scopus 로고    scopus 로고
    • US Preventive Services Task Force, Screening for prostate cancer: US Preventive Services Task Force recommendation statement
    • US Preventive Services Task Force, Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 149 (2008) I37
    • (2008) Ann Intern Med , vol.149
  • 31
    • 72149130350 scopus 로고    scopus 로고
    • ¿Hay que recomendar cribado de cáncer de próstata en individuos asintomáticos?
    • Brenes F.J. ¿Hay que recomendar cribado de cáncer de próstata en individuos asintomáticos?. Siete Días Médicos 699 (2007) 48-52
    • (2007) Siete Días Médicos , vol.699 , pp. 48-52
    • Brenes, F.J.1
  • 32
    • 34648851429 scopus 로고    scopus 로고
    • Comprensión de un documento que informa a los ciudadanos sobre los beneficios y los riesgos del cribado para el cáncer del próstata. Estudio mediante entrevistas semiestructuradas. Grupo investigador DECIDIU-PSA
    • Fernández de Sanmamed M.J., Ballester Torrens M., Ariza González F., and Casajuana Brunet J. Comprensión de un documento que informa a los ciudadanos sobre los beneficios y los riesgos del cribado para el cáncer del próstata. Estudio mediante entrevistas semiestructuradas. Grupo investigador DECIDIU-PSA. Rev Esp Salud Pública 81 (2007) 289-305
    • (2007) Rev Esp Salud Pública , vol.81 , pp. 289-305
    • Fernández de Sanmamed, M.J.1    Ballester Torrens, M.2    Ariza González, F.3    Casajuana Brunet, J.4
  • 33
    • 38049031795 scopus 로고    scopus 로고
    • Screening for prostate cancer in US men ACPM position statement on preventive practice
    • Lim L.S., and Sherin K. Screening for prostate cancer in US men ACPM position statement on preventive practice. Am J Prev Med 34 (2008) 164-170
    • (2008) Am J Prev Med , vol.34 , pp. 164-170
    • Lim, L.S.1    Sherin, K.2
  • 34
    • 17844374088 scopus 로고    scopus 로고
    • La mortalidad por cáncer de próstata en Andalucía: aportaciones al cribado poblacional
    • Ruiz-Ramos M., and Escolar A. La mortalidad por cáncer de próstata en Andalucía: aportaciones al cribado poblacional. Actas Urol Esp 29 (2005) 41-46
    • (2005) Actas Urol Esp , vol.29 , pp. 41-46
    • Ruiz-Ramos, M.1    Escolar, A.2
  • 37
    • 37649021276 scopus 로고    scopus 로고
    • Hiperplasia benigna de próstata: manejo y abordaje por el médico de AP
    • Brenes F.J., and Ródenas J.L. Hiperplasia benigna de próstata: manejo y abordaje por el médico de AP. Aula Acreditada El Médico 842 (2002) 23-46
    • (2002) Aula Acreditada El Médico , vol.842 , pp. 23-46
    • Brenes, F.J.1    Ródenas, J.L.2
  • 39
    • 37649022536 scopus 로고    scopus 로고
    • El envejecimiento de la vejiga: cambios en la dinámica de la continencia y la micción
    • Pérez F.C., Pérez J., De las Heras A.I., and Pérez G. El envejecimiento de la vejiga: cambios en la dinámica de la continencia y la micción. Arch Med 1 (2005) 26
    • (2005) Arch Med , vol.1 , pp. 26
    • Pérez, F.C.1    Pérez, J.2    De las Heras, A.I.3    Pérez, G.4
  • 41
    • 0034329582 scopus 로고    scopus 로고
    • Alpha blockers: Are all created equal?
    • Debruyne F.M. Alpha blockers: Are all created equal?. Urology 56 (2000) 20-22
    • (2000) Urology , vol.56 , pp. 20-22
    • Debruyne, F.M.1
  • 42
    • 0032991607 scopus 로고    scopus 로고
    • A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
    • Djavan B., and Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36 (1999) 1-13
    • (1999) Eur Urol , vol.36 , pp. 1-13
    • Djavan, B.1    Marberger, M.2
  • 43
    • 0012915054 scopus 로고    scopus 로고
    • Tratamiento farmacológico de la hiperplasia benigna de próstata basado en la evidencia
    • Postius J., and Castro D. Tratamiento farmacológico de la hiperplasia benigna de próstata basado en la evidencia. Rev Clin Esp 199 (1999) 58-61
    • (1999) Rev Clin Esp , vol.199 , pp. 58-61
    • Postius, J.1    Castro, D.2
  • 44
    • 0037434553 scopus 로고    scopus 로고
    • Initial treatment of hypertension
    • August P. Initial treatment of hypertension. N Engl J Med 348 (2003) 610-617
    • (2003) N Engl J Med , vol.348 , pp. 610-617
    • August, P.1
  • 45
    • 0037612365 scopus 로고    scopus 로고
    • Finasterida: diez años de uso clínico. Revisión sistemática de la literatura
    • Jiménez J.F., Quecedo L., and Llano J. Finasterida: diez años de uso clínico. Revisión sistemática de la literatura. Actas Urol Esp 27 (2003) 202-215
    • (2003) Actas Urol Esp , vol.27 , pp. 202-215
    • Jiménez, J.F.1    Quecedo, L.2    Llano, J.3
  • 46
    • 0038311875 scopus 로고    scopus 로고
    • Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia
    • Andriole G.L., and Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44 (2003) 82-88
    • (2003) Eur Urol , vol.44 , pp. 82-88
    • Andriole, G.L.1    Kirby, R.2
  • 47
    • 0036754256 scopus 로고    scopus 로고
    • Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    • Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
    • (2002) Urology , vol.60 , pp. 434-441
    • Roehrborn, C.G.1    Boyle, P.2    Nickel, J.C.3    Hoefner, K.4    Andriole, G.5
  • 48
    • 38849201263 scopus 로고    scopus 로고
    • The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
    • Roehrborn C.G., Siami P., Barkin J., Damiao R., Major-Walker K., Morrill B., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179 (2008) 616-621
    • (2008) J Urol , vol.179 , pp. 616-621
    • Roehrborn, C.G.1    Siami, P.2    Barkin, J.3    Damiao, R.4    Major-Walker, K.5    Morrill, B.6
  • 50
    • 0037404941 scopus 로고    scopus 로고
    • Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
    • Hugosson J., Aus G., Lilja H., Lodding P., Pihl C.G., and Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 169 (2003) 1720-1723
    • (2003) J Urol , vol.169 , pp. 1720-1723
    • Hugosson, J.1    Aus, G.2    Lilja, H.3    Lodding, P.4    Pihl, C.G.5    Pileblad, E.6
  • 51
    • 0041828739 scopus 로고    scopus 로고
    • Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less
    • Ito K., Yamamoto T., Ohi M., Takechi H., Kurokawa K., Suzuki K., et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less. Prostate 57 (2003) 8-13
    • (2003) Prostate , vol.57 , pp. 8-13
    • Ito, K.1    Yamamoto, T.2    Ohi, M.3    Takechi, H.4    Kurokawa, K.5    Suzuki, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.